GI Dynamics Inc  

(Public, ASX:GID)   Watch this stock  
Find more results for GID
0.0200
0.0000 (0.00%)
May 26 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.02 - 0.02
52 week 0.01 - 0.17
Open 0.02
Vol / Avg. 4.89M/540,406.00
Mkt cap 9.41M
P/E     -
Div/yield     -
EPS -0.08
Shares 9.51M
Beta     -
Inst. own     -
Jun 8, 2016
GI Dynamics Inc Annual Shareholders Meeting (Estimated) - 9:00AM GMT+10 - Add to calendar
May 23, 2016
GI Dynamics Inc Annual Shareholders Meeting - Webcast
May 12, 2016
Q1 2016 GI Dynamics Inc Earnings Call - Webcast
Apr 29, 2016
Q1 2016 GI Dynamics Inc Earnings Release
Mar 16, 2016
GI Dynamics Announces Top-Line Results from U.S. Pivotal Clinical Trial of EndoBarrier´┐Ż Therapy (the ENDO Trial) Conference Call - Webcast
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -1644.98% -2671.81%
Operating margin -1657.89% -2622.04%
EBITD margin - -2555.55%
Return on average assets -69.82% -86.52%
Return on average equity -82.67% -102.76%
Employees 36 -
CDP Score - -

Address

1 Maguire Rd
LEXINGTON, MA 02421-3114
United States - Map
+1-781-3573310 (Phone)
+1-781-3573301 (Fax)

Website links

Description

GI Dynamics, Inc. designs, develops, and markets medical devices for non-surgical approaches to treating type 2 diabetes and obesity. The Company has commercially launched its lead product, the EndoBarrier. EndoBarrier Therapy is a treatment for people whose diabetes medications are no longer effective, who are at risk for serious health complications from their diabetes and excess weight and who want to avoid surgery or the progression to injectable therapy. The Company’s product is sold to customers located in Europe, the Middle East, Australia and South America. The Company is focused on the commercial rollout of the EndoBarrier in selected countries in Europe and South America, as well as in Australia and Israel. In the United States, it has received approval from the United States Food and Drug Administration (FDA), to commence its clinical trial, which began in 2013.

Officers and directors

Scott Schorer President, Chief Executive Officer
Age: 47
James B. Murphy Chief Financial Officer, Treasurer, Company Secretary
Age: 59
Brian Callahan Executive Vice President - Clinical, Regulatory and Quality, Chief Compliance Officer
Age: 49
Karl-Heinz Blohm Ph.D. Vice President - International Sales
Daniel Jeffrey Moore Non-Executive Chairman of the Board
Age: 53
Michael A. Carusi Non-Independent Non-Executive Director
Age: 49
Jack Edward Meyer Non-Executive Director
Age: 71
Graham John Bradley Independent Non-Executive Director
Age: 66
Anne Jillian Keating Independent Non-Executive Director
Age: 61